Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: A randomized, double blind, placebo-controlled, multicenter clinical study

Table 1 Liver fibrotic scores before and after therapy based on Semi-quantitative Scoring System

Group	Before	After	Before-after	Comparison before therapy		Comparison within group		Comparison between groups
				Statistics	P	Statistics	P	Statistics	P
A
(n = 25)	6.76 ± 6.67	4.72 ± 5.63	2.04 ± 2.59			96.0	0.0001
B				1.4098	0.1586			4.8834	0
(n = 24)	4.13 ± 2.82	6.33 ± 4.04	-2.21 ± 3.72			83.0	0.0009

Table 2 Liver histologic activity scores before and after therapy based on Semi-quantitative Scoring System

Group	Before	After	Before-after	Comparison before therapy		Comparison within group		Comparison between groups
				Statistics	P	Statistics	P	Statistics	P
A
(n = 25)	6.08 ± 3.84	4.00 ± 2.97	2.08 ± 2.71			69.5	0.0002
B				0.0407	0.9675			3.3543	0.0008
(n = 24)	6.08 ± 4.06	6.92 ± 4.17	-0.83 ± 3.38			21.5	0.2344

Table 3 Comparison of histopathology of hepatic fibrosis

Group	Distinctly effective	Effective	Ineffect-ive	Comparison between 2 groups
				Statitics χ2	P
A	6	6	13
(n = 25)	(24.00%)	(24.00%)	(52.00%)
B	0	1	23	12.6970	0.0004
(n = 24)	(0.00%)	(4.17%)	(95.83%)

Table 4 Comparison of noninvasive markers of hepatic fibrosis

Group	Distinctly effective	Effective	Ineffect-ive	Comparison between 2 groups
				Statitics χ2	P
A	2	42	22
(n = 66)	(3.03%)	(63.64%)	(33.33%)
B	0	20	46	16.2494	0.0001
(n = 66)	(0.00%)	(30.30%)	(69.70%)